Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 12;187(25):7285-7302.e29.
doi: 10.1016/j.cell.2024.09.048. Epub 2024 Oct 30.

IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion

Affiliations
Free article

IRGQ-mediated autophagy in MHC class I quality control promotes tumor immune evasion

Lina Herhaus et al. Cell. .
Free article

Abstract

The autophagy-lysosome system directs the degradation of a wide variety of cargo and is also involved in tumor progression. Here, we show that the immunity-related GTPase family Q protein (IRGQ), an uncharacterized protein to date, acts in the quality control of major histocompatibility complex class I (MHC class I) molecules. IRGQ directs misfolded MHC class I toward lysosomal degradation through its binding mode to GABARAPL2 and LC3B. In the absence of IRGQ, free MHC class I heavy chains do not only accumulate in the cell but are also transported to the cell surface, thereby promoting an immune response. Mice and human patients suffering from hepatocellular carcinoma show improved survival rates with reduced IRGQ levels due to increased reactivity of CD8+ T cells toward IRGQ knockout tumor cells. Thus, we reveal IRGQ as a regulator of MHC class I quality control, mediating tumor immune evasion.

Keywords: GABARAPL2; IRGQ; LC3B; MHC class I; autophagy; hepatocellular carcinoma; immune evasion; quality control.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests J.W.H. is a co-founder and consultant for Caraway Therapeutics (a subsidiary of Merck Inc) and is a scientific advisory board member for Lyterian Therapeutics.

MeSH terms

Substances